The purpose of this study is to determine whether thiopurine S-methyltransferase (TPMT)
genotyping prior to thiopurine use is cost-effective in patients with inflammatory bowel
disease (IBD) in need of immune suppression.
The study is designed to test the hypothesis that optimization of initial thiopurine dose
based on pre-treatment TPMT genotyping will maximize treatment efficacy and minimize adverse
drug reactions (ADRs) resulting in reduced costs.
Phase:
N/A
Details
Lead Sponsor:
ZonMw: The Netherlands Organisation for Health Research and Development